المؤلفون: Scottish Diabetes Research Network (SDRN) Epidemiology group

المساهمون: University of Aberdeen.Other Applied Health Sciences, University of Aberdeen.Centre for Health Data Science

مصطلحات موضوعية: SDG 3 - Good Health and Well-being, Diabetes mellitus type 1, Flash monitoring, HbA, Hypoglycaemia, Ketoacidosis, R Medicine (General), Internal Medicine, Endocrinology, Diabetes and Metabolism, Other, 17/0005627, Chief Scientist Office (CSO), ETM/47, R1

الوصف: Funding Information: This study was supported by funding from the Diabetes UK (17/0005627) and the Chief Scientist Office (Ref. ETM/47). ; Peer reviewed

وصف الملف: application/pdf

العلاقة: Diabetologia; 208275320; 5440641b-d706-422a-a667-db374883ecae; 85116769727; 000705705300002; Scottish Diabetes Research Network (SDRN) Epidemiology group 2022 , ' Flash monitor initiation is associated with improvements in HbA 1c levels and DKA rates among people with type 1 diabetes in Scotland : a retrospective nationwide observational study ' , Diabetologia , vol. 65 , no. 1 , pp. 159–172 . https://doi.org/10.1007/s00125-021-05578-1Test; ORCID: /0000-0001-6164-211X/work/102920098; PubMedCentral: PMC8660764; https://hdl.handle.net/2164/17460Test; http://www.scopus.com/inward/record.url?scp=85116769727&partnerID=8YFLogxKTest

الإتاحة: https://doi.org/10.1007/s00125-021-05578-1Test
https://hdl.handle.net/2164/17460Test
http://www.scopus.com/inward/record.url?scp=85116769727&partnerID=8YFLogxKTest

المؤلفون: Scottish Diabetes Research Network (SDRN) Epidemiology Group, Colin Fischbacher, Helen Colhoun

المصدر: Colhoun, H M & Wild, S 2009, ' Use of insulin glargine and cancer incidence in Scotland : a study from the Scottish Diabetes Research Network Epidemiology Group ', Diabetologia, vol. 52, no. 9, pp. 1755-65 . https://doi.org/10.1007/s00125-009-1453-1Test
Diabetologia

مصطلحات موضوعية: Male, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Insulin Glargine, 0302 clinical medicine, Neoplasms, Insulin, Glargine, Registries, Cancer, 0303 health sciences, education.field_of_study, Diabetes, Chromosome Mapping, 3. Good health, Insulin, Long-Acting, 030220 oncology & carcinogenesis, Cohort, Female, Erratum, medicine.drug, medicine.medical_specialty, Population, 030209 endocrinology & metabolism, Breast Neoplasms, Article, Diabetes Complications, 03 medical and health sciences, Breast cancer, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, Hypoglycemic Agents, education, 030304 developmental biology, Probability, Retrospective Studies, Insulin glargine, business.industry, Retrospective cohort study, medicine.disease, Survival Analysis, Cancer registry, Endocrinology, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Scotland, business

الوصف: Aims/hypothesis The aim of the present study was to examine whether patients with diabetes in Scotland using insulin glargine have a greater cancer risk than patients using other types of insulin. Methods We used a nationwide diabetes clinical database that covers the majority of the Scottish population with diagnosed diabetes, and examined patients with diabetes who were exposed to any insulin therapy between 1 January 2002 and 31 December 2005. Among these we defined a fixed cohort based on exposure during a 4 month period in 2003 (n = 36,254, in whom 715 cases of cancer occurred) and a cohort of new insulin users across the period (n = 12,852 in whom 381 cancers occurred). Records from these cohorts were linked to cancer registry data up to the end of 2005. We used Cox proportional hazards models for survival analyses. Results Those receiving any insulin glargine (n = 3,959) had the same incidence rate for all cancers as those not receiving insulin glargine (HR 1.02, 95% CI 0.77–1.36, p = 0.9 in the fixed cohort) The subset of patients using insulin glargine alone (n = 447) had a significantly higher incidence of all cancers than those using other insulins only (n = 32,295) (HR 1.55, 95% CI 1.01–2.37, p = 0.045), and those using insulin glargine with other insulins (n = 3,512) had a slightly lower incidence (HR 0.81, 95% CI 0.55–1.18, p = 0.26). There were important differences in baseline characteristics between these three groups, although the risk ratios were broadly unaltered on adjustment for these. Overall, there was no increase in breast cancer rates associated with insulin glargine use (HR 1.49, 95% CI 0.79–2.83, though insulin glargine only users had a higher rate than those using non-glargine insulin only (HR 3.39, 95% CI 1.46–7.85, p = 0.004). Among type 2 diabetic incident insulin users, no significant difference between the three groups was observed with respect to all cancer or breast cancer. All the above HRs are adjusted for age, calendar time prior cancer and type of diabetes, as appropriate, and are stratified according to sex. Conclusions/interpretation Overall, insulin glargine use was not associated with an increased risk of all cancers or site-specific cancers in Scotland over a 4 year time frame. Given the overall data, we consider the excess of cases of all cancers and breast cancer in the subgroup of insulin glargine only users to more likely reflect allocation bias rather than an effect of insulin glargine itself. Electronic supplementary material The online version of this article (doi:10.1007/s00125-009-1453-1) contains supplementary material, which is available to authorised users.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7db6c0ade8880362596cc5e3f1d76606Test
https://pubmed.ncbi.nlm.nih.gov/28512700Test